Monopar Therapeutics Inc.
MNPR
$59.27
-$1.72-2.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.99% | -200.27% | -142.96% | -117.78% | -85.50% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.49% | 540.20% | 375.08% | 283.39% | 199.51% |
| Change in Net Operating Assets | -174.49% | 106.93% | 87.76% | 60.10% | 358.36% |
| Cash from Operations | -90.52% | -81.96% | -43.92% | -43.76% | 18.51% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -342.54% | -625.28% | -733.56% | -377.63% | -390.98% |
| Cash from Investing | -342.54% | -625.28% | -733.56% | -377.63% | -390.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 115.15% | 5,108.54% | 1,384.46% | 1,164.72% | 2,763.59% |
| Repurchase of Common Stock | -34,692.41% | -84,373.18% | -1,467.54% | -450.25% | -121.96% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 54.45% | 4,143.44% | 1,383.74% | 1,171.36% | 2,824.84% |
| Foreign Exchange rate Adjustments | 19,340.00% | -48.78% | -11.11% | 127.27% | 102.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -58.45% | 24,000.08% | 3,149.14% | 1,432.37% | 4,289.79% |